You are here: Industry Insights > NMOSD

News List

Soliris (Eculizumab) Injection Approved to Treat Neuromyelitis Optica Spectrum Disorder drugs
July 01, 2019
Soliris (Eculizumab) Injection Approved to Treat Neuromyelitis Optica Spectrum Disorder.
FDA approves first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system worldpharmanews
July 01, 2019
FDA approves first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system.
Alexion Receives FDA Approval of Soliris (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder drugs
June 28, 2019
Alexion Receives FDA Approval of Soliris (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder.
Alexion aims for fourth rare disease use for blockbuster Soliris pharmaphorum
February 27, 2019
The FDA has granted a fast review for Alexion Pharmaceuticals’ filing for its Soliris, as a treatment for a rare neurological disease that leads to worsening disability, blindness, paralysis, and possibly early death.
Chugai preps filings for IL-6 drug in rare disease, chasing Soliris fiercebiotech
December 20, 2018
Chugai has the positive phase 3 data it needs to file IL-6-targeting antibody satralizumab for approval in neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease, next year.

Previous page 1 2 Next page